FDA Approves Regeneron Myasthenia Gravis Shot Given 4 Times a Year

The US Food and Drug Administration has approved Livsayis (cemdisiran), a Regeneron drug for adults with generalized myasthenia gravis who test positive for antibodies to the acetylcholine receptor. Regeneron announced the decision on Nov. 18. The company said it is its first approved medicine in neurology and its first approved siRNA therapy.
What happened
Livsayis is a small interfering RNA that lowers levels of a complement protein called C5 in the blood. Regeneron said it is the only FDA-approved treatment for the disease that is given under the skin four times a year. It is also the first and only approved siRNA therapy for the condition, according to the company.
The approval rests on the phase 3 NIMBLE trial. AJMC reported that the primary analysis included 123 patients, 93% of whom had the receptor antibodies. Regeneron reported these results at 24 weeks:
- Daily living scores (MG-ADL) improved by 4.5 points on Livsayis, compared with 2.2 points on placebo.
- 76.6% of patients on the drug improved by at least 3 points on that scale, compared with 44.1% on placebo.
- Muscle strength scores (QMG) improved by 4.2 points, compared with 1.5 points on placebo.
- 48.4% improved by at least 5 QMG points, compared with 19.0% on placebo.
The trial also tested the drug with a C5 antibody, pozelimab. AJMC reported that the pairing beat placebo but gave no numerical edge over Livsayis alone.
The label carries a boxed warning for serious meningococcal infections, which Regeneron said matches other drugs that reduce C5 activity. The drug is only available through a restricted safety program. AJMC reported that serious infections occurred in 5% of treated patients in the trial and its extension, including one death from pneumonia.
Why it matters
Regeneron says the disease affects about 85,000 people in the US. Analysts at Truist called the dosing schedule a practical point of difference, BioSpace reported. BMO Capital Markets wrote that the approval adds a modest growth driver for Regeneron.
The drug is licensed from Alnylam Pharmaceuticals. Regeneron said it alone handles development, manufacturing and sales worldwide under that deal. A decision in the European Union is expected in the second half of 2027, and filings in other markets, including Japan, are planned.
What it means for people in the industry
Regeneron did not give a US launch date or a price. It is offering patient support, including insurance checks, through its myRARE program.
For people working in neurology, rare disease sales, medical affairs and drug safety, things to watch include the launch timing, the price and how the restricted safety program is run. Results from the ongoing NIMBLE trial may also add to the picture.
See open pharma jobs in the US and Canada
Sources
- Livsayis (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing, Regeneron (news release via BioSpace)
- FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis, AJMC
- Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug, BioSpace
Check Your Supplement Interactions
Use our AI-powered checker to analyze supplement safety and interactions.
Open Interaction Checker →Comments (0)
This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.